PTC Therapeutics, Inc. (PTCT) Shares Bought by Metropolitan Life Insurance Co. NY

Metropolitan Life Insurance Co. NY raised its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 13.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,769 shares of the biopharmaceutical company’s stock after acquiring an additional 1,753 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in PTC Therapeutics were worth $498,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. Scopia Capital Management LP grew its position in PTC Therapeutics by 42.7% in the 1st quarter. Scopia Capital Management LP now owns 5,914,052 shares of the biopharmaceutical company’s stock valued at $160,034,000 after acquiring an additional 1,770,782 shares during the last quarter. BlackRock Inc. grew its position in PTC Therapeutics by 5.2% in the 2nd quarter. BlackRock Inc. now owns 3,452,161 shares of the biopharmaceutical company’s stock valued at $116,441,000 after acquiring an additional 170,451 shares during the last quarter. FMR LLC grew its position in PTC Therapeutics by 16.8% in the 2nd quarter. FMR LLC now owns 1,303,254 shares of the biopharmaceutical company’s stock valued at $43,959,000 after acquiring an additional 187,900 shares during the last quarter. Millennium Management LLC grew its position in PTC Therapeutics by 22.0% in the 1st quarter. Millennium Management LLC now owns 677,501 shares of the biopharmaceutical company’s stock valued at $18,333,000 after acquiring an additional 122,296 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in PTC Therapeutics by 32.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 295,635 shares of the biopharmaceutical company’s stock valued at $9,972,000 after acquiring an additional 72,308 shares during the last quarter. 85.47% of the stock is currently owned by institutional investors.

Shares of NASDAQ PTCT opened at $46.87 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.34 and a quick ratio of 4.18. The firm has a market cap of $2.31 billion, a P/E ratio of -23.20 and a beta of 1.95. PTC Therapeutics, Inc. has a 1-year low of $14.87 and a 1-year high of $52.95.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.15. The firm had revenue of $68.74 million during the quarter, compared to analysts’ expectations of $69.83 million. PTC Therapeutics had a negative return on equity of 27.41% and a negative net margin of 25.03%. equities analysts forecast that PTC Therapeutics, Inc. will post -1.48 EPS for the current fiscal year.

Several equities research analysts have weighed in on PTCT shares. Royal Bank of Canada upgraded PTC Therapeutics from a “sector perform” rating to an “outperform” rating and set a $11.00 target price for the company in a report on Monday, June 18th. ValuEngine upgraded PTC Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, June 18th. Credit Suisse Group upped their target price on PTC Therapeutics from $49.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, September 5th. William Blair upgraded PTC Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday, June 18th. Finally, Citigroup reiterated a “buy” rating and issued a $50.00 target price (up from $35.00) on shares of PTC Therapeutics in a report on Tuesday, July 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $33.43.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.

Featured Story: Terms to Better Understand Call Options

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply